Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gestoden, an innovative progestogen.

G Hoppe

    Advances in Contraception : the Official Journal of the Society for the Advancement of Contraception
    |June 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Gestoden, a novel progestogen, offers enhanced biological activity for lower-dose oral contraceptives. This new synthetic progestogen exhibits a unique anti-mineralocorticoid action, improving the therapeutic profile of birth control pills.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Prenatal adversity: a risk factor in borderline personality disorder?

    Psychological medicine·2012
    Same author

    Accumulation of oxidized lipid-protein complexes alters phagosome maturation in retinal pigment epithelium.

    Cellular and molecular life sciences : CMLS·2004
    Same author

    Oxidized low density lipoprotein-induced inhibition of processing of photoreceptor outer segments by RPE.

    Investigative ophthalmology & visual science·2001
    Same author

    Macrophage receptors responsible for distinct recognition of low density lipoprotein containing pyrrole or pyridinium adducts: models of oxidized low density lipoprotein.

    Journal of lipid research·2000
    Same author

    Non-conventional modification of low density lipoproteins: chemical models for macrophage recognition of oxidized LDL.

    Biochimica et biophysica acta·1998
    Same author

    Oxidation products of cholesteryl linoleate are resistant to hydrolysis in macrophages, form complexes with proteins, and are present in human atherosclerotic lesions.

    Journal of lipid research·1997
    Same journal

    Research and quality control in natural family planning with relational database systems.

    Advances in contraception : the official journal of the Society for the Advancement of Contraception·2001
    Same journal

    Contraceptive methods used and preferred by men and women.

    Advances in contraception : the official journal of the Society for the Advancement of Contraception·2001
    Same journal

    A decade of experience with TCu200.

    Advances in contraception : the official journal of the Society for the Advancement of Contraception·2001
    Same journal

    Fine structure of the langur monkey vas deferens and possible role of changes following vasectomy in the success or failure of the vasovasostomy.

    Advances in contraception : the official journal of the Society for the Advancement of Contraception·2001
    Same journal

    Factors affecting contraceptive use and behavior in Kocaeli, Turkey.

    Advances in contraception : the official journal of the Society for the Advancement of Contraception·2001
    Same journal

    Initial UK experience of the levonorgestrel-releasing contraceptive intravaginal ring.

    Advances in contraception : the official journal of the Society for the Advancement of Contraception·2001
    See all related articles

    Area of Science:

    • Endocrinology
    • Pharmacology
    • Reproductive Health

    Background:

    • Oral contraceptives (OCs) commonly use synthesized estrogen and various progestogens.
    • Levonorgestrel is a standard progestogen in low-dose OCs, with modifications like norgestimate and desogestrel showing limited improvement.
    • Further dose reduction in OCs is challenging due to the limitations of existing progestogens.

    Purpose of the Study:

    • To introduce and evaluate gestoden, a novel progestogen synthesized by Schering AG.
    • To highlight gestoden's enhanced biological activity and unique pharmacological profile compared to existing progestogens.
    • To present clinical trial results of a new monophasic oral contraceptive containing gestoden.

    Main Methods:

    • Synthesis of gestoden, a new progestogen derived from the levonorgestrel class.

    Related Experiment Videos

  • Development of a fixed-combination oral contraceptive pill with a reduced progestogen dose.
  • Clinical trials to assess the efficacy and safety of the gestoden preparation.

    • Main Results:

    • Gestoden demonstrates significantly enhanced biological activity, enabling a 50% lower progestogen dose in combination pills.
    • Gestoden exhibits an improved pharmacological profile with dissociated androgenic and progestogenic activities.
    • A unique anti-mineralocorticoid effect, similar to natural progesterone, was observed, differentiating it from other synthetic progestogens.

    Conclusions:

    • Gestoden represents a significant advancement in progestogen development for oral contraceptives.
    • The enhanced activity and unique properties of gestoden allow for lower effective doses and improved safety profiles.
    • Clinical trials support the use of gestoden in new low-dose oral contraceptive formulations.